Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 2×
“Several in vitro studies have shown that GSK-3β is expressed in neurons and that it may induce tau phosphorylation [ 16 , 24, 29, 31, 33, 34, 35, 36, 39, 42].”
BackgroundGlycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau
Mandelkow, E.-M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., & Mandelkow, E. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81496-9 · Cited by 515 · cited 2×
“Several in vitro studies have shown that GSK-3β is expressed in neurons and that it may induce tau phosphorylation [16, 24 , 29, 31, 33, 34, 35, 36, 39, 42].”
BackgroundZhu, X., Rottkamp, C. A., Boux, H., Takeda, A., Perry, G., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.10.880 · Cited by 378
Pei, J.-J., Grundke-Iqbal, I., Iqbal, K., Bogdanovic, N., Winblad, B., & Cowburn, R. F. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00296-0 · Cited by 226
Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells
Sperbera, B. R., Leight, S., Goedert, M., & Lee, V. M.-Y. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11902-9 · Cited by 204
Cited by
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,517
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536
“ogy and correlates with disease stage [7,8].”
Nuclear speckles: molecular organization, biological function and role in disease
Galganski, L., Urbanek, M. O., & Krzyzosiak, W. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx759 · Cited by 499
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Ferrer, I., Rovira, M. B., Guerra, M. L. S., Rey, M. J., & Costa‐Jussá, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00493.x · Cited by 479
Self-citationGriffin, R. J., Moloney, A., Kelliher, M., Johnston, J. A., Ravid, R., Dockery, P., O'Connor, R., & O'Neill, C. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02949.x · Cited by 459
“1999) and inactive GSK3b (pS9) (Ferrer et al. 2002) associated with NFTs in AD.”
BackgroundResultLeroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404
Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329
“Its overexpression produces tau hyperphosphorylation and neurodegeneration in transgenic mice [4], and it seems to be upregulated in the hippocampus of AD patients [5], spreading out over the cortex in parallel with the accumulation of neurofibrillary tangles [6] and other AD lesions [7].”
Ferrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Self-citationRole of tau protein in Alzheimer’s disease: The prime pathological player
Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278
Ferrer, I., Santpere, G., & van Leeuwen, F. W. (2008) · Brain · doi:10.1093/brain/awm305 · Cited by 254
Self-citationGSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway
Inoue, K., Rispoli, J., Kaphzan, H., Klann, E., Chen, E. I., Kim, J., Komatsu, M., & Abeliovich, A. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-48 · Cited by 168
Kitazawa, M., Cheng, D., & LaFerla, F. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05901.x · Cited by 165
Chang, K.-A., Kim, H.-S., Ha, T.-Y., Ha, J.-W., Shin, K. Y., Jeong, Y. H., Lee, J.-P., Park, C.-H., Kim, S., Baik, T.-K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02393-05 · Cited by 161
Activation of mTOR: a culprit of Alzheimer’s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161
Höglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161
Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice
Ikeda, M., Kawarai, T., Kawarabayashi, T., Matsubara, E., Murakami, T., Sasaki, A., Tomidokoro, Y., Ikarashi, Y., Kuribara, H., Ishiguro, K., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62274-2 · Cited by 120
“The accumulated tau R406W in our Tg mouse model therefore has phosphorylated sites in common with those observed in FTDP-17 and Alzheimer’s disease.(23,47) The expression level of tau R406W was about 80% that of the endogenous mouse tau levels by Western blot analysis.”
BackgroundResultInfluentialRational therapeutic approaches to progressive supranuclear palsy
Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91
The septo-hippocampal system, learning and recovery of function
Niewiadomska, G., Baksalerska-Pazera, M., & Riedel, G. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.03.039 · Cited by 67
“2006), residentaxonalproteins suchasneurofilaments and tau, glycogen (Ferrer et al., 2002), and organelles (Ghribi, 2006; Baloyannis, 2006), in”
Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer’s disease
Riise, J., Plath, N., Pakkenberg, B., & Parachikova, A. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-015-1375-7 · Cited by 66
Ferrer, I., Barrachina, M., Tolnay, M., Rey, M. J., Vidal, N., Carmona, M., Blanco, R., & Puig, B. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00007.x · Cited by 60
Self-citationMateo, I., Infante, J., Llorca, J., Rodríguez, E., Berciano, J., & Combarros, O. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091044 · Cited by 53
Knockout mice in understanding the mechanism of action of lithium
Agam, G., Bersudsky, Y., Berry, G. T., Moechars, D., Lavi-Avnon, Y., & Belmaker, R. H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371121 · Cited by 50
Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation
Ferrer, I., Pastor, P., Rey, M. J., Muñoz, E., Puig, B., Pastor, E., Oliva, R., & Tolosa, E. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00435.x · Cited by 48
Self-citationZhang, L., Dong, H., Si, Y., Wu, N., Cao, H., Mei, B., & Meng, B. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.011 · Cited by 39
Damjanac, M., Rioux Bilan, A., Paccalin, M., Pontcharraud, R., Fauconneau, B., Hugon, J., & Page, G. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.09.008 · Cited by 32
Interaction Between Eye Pigment Genes and Tau-Induced Neurodegeneration in Drosophila melanogaster
Ambegaokar, S. S., & Jackson, G. R. (2010) · Genetics · doi:10.1534/genetics.110.119545 · Cited by 30
López‐González, I., Carmona, M., Blanco, R., Luna‐Muñoz, J., Martínez‐Mandonado, A., Mena, R., & Ferrer, I. (2013) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00627.x · Cited by 28
Self-citationGSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer
Silva-García, O., Cortés-Vieyra, R., Mendoza-Ambrosio, F. N., Ramírez-Galicia, G., & Baizabal-Aguirre, V. M. (2020) · Biomolecules · doi:10.3390/biom10121683 · Cited by 17
Metadata
- Authors
- Ferrer, I., Barrachina, M., & Puig, B.
- Venue
- Acta Neuropathologica
- Published
- 2002-12
- Volume
- 104
- Issue
- 6
- Pages
- 583-591
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W1532078866
- Cited by
- 196
- References
- 5
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.